HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) — FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and […]
Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patients Established a research […]
NO-HEADQUARTERS/REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) — PubMatic (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply […]